一、 计提减值准备情况概述 证券代码：688075 证券简称：安旭生物 公告编号：2025-008 为真实反应杭州安旭生物科技股份有限公司（以下简称"公司"）2024 年度 资产和财务状况，根据《企业会计准则》及公司会计政策的相关规定，公司及下属 子公司对截至 2024 年 12 月 31 日的各项资产进行了全面清查，通过分析、评估， 基于审慎性原则，对存在减值迹象的相关资产进行了减值测试并计提相应的减值准 备。公司 2024 年度计提各项资产减值准备合计 2,532.77 万元。本次计提资产减值 准备需提交股东大会审议。明细如下： 杭州安旭生物科技股份有限公司 关于 2024 年度计提资产减值准备的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 杭州安旭生物科技股份有限公司（以下简称"公司"）于 2025 年 4 月 28 日 召开第二届董事会第十七次会议、第二届监事会第十五次会议，分别审议通过了 《关于 2024 年度计提资产减值准备的议案》。现将相关事项公告如下： （一） 信用减值减值损失 公司 2024 年度 ...

证券代码：688075 证券简称：安旭生物 公告编号：2025-011 杭州安旭生物科技股份有限公司 关于召开2024年年度股东大会的通知 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 一、 召开会议的基本情况 （一） 股东大会类型和届次 2024年年度股东大会 召开日期时间：2025 年 5 月 22 日 14 点 00 分 召开地点：浙江省杭州市莫干山路 1418-50 号 4 幢 5 楼大会议室 （五） 网络投票的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股东大会网络投票系统 网络投票起止时间：自2025 年 5 月 22 日 至2025 年 5 月 22 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 东大会召开当日的交易时间段，即 9:15-9:25,9:30-11:30，13:00-15:00；通过互联 网投票平台的投票时间为股东大会召开当日的 9:15-15:00。 （六） 融资融券、转融通、约定购回业务账户和沪股通投资者的投票程序 股东大会召开日期：20 ...

证券代码：688075 证券简称：安旭生物 公告编号：2025-003 杭州安旭生物科技股份有限公司 第二届监事会第十五次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责 任。 一、监事会会议召开情况 根据《证券法》、中国证监会《公开发行证券的公司信息披露内容与格式准 则第 2 号——年度报告的内容与格式》和《上海证券交易所科创板股票上市规则》 等规则要求，我们在全面审阅公司 2024 年年度报告后，发表意见如下： 1、公司 2024 年年度报告的编制和审核程序符合法律、法规及《公司章程》 等相关规定，公司 2024 年年度报告包含的信息公允、全面、真实地反映了公司本 报告期的财务状况和经营成果等事项。 2、我们保证公司 2024 年年度报告内容真实、准确、完整，不存在任何虚假 记载、误导性陈述或者重大遗漏。并对其内容的真实性、准确性和完整性承担个 别和连带的法律责任。 表决结果：同意 3 票，反对 0 票，弃权 0 票。 1 本议案尚需提交公司 2024 年年度股东大会审议。 杭州安旭生物科技股份有限公司（以下简 ...

证券代码：688075 证券简称：安旭生物 公告编号：2025-002 杭州安旭生物科技股份有限公司 第二届董事会第十七次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、董事会会议召开情况 杭州安旭生物科技股份有限公司（以下简称"公司"或"安旭生物"）第二届董事 会第十七次会议通知于 2025 年 4 月 18 日以邮件方式发出送达全体董事，会议于 2025 年 4 月 28 日以现场表决方式召开，会议由公司董事长凌世生先生主持，会议 应到董事 7 人，实到董事 7 人。本次会议的召集、召开符合《中华人民共和国公司 法》等法律、法规、规章、规范性文件和《公司章程》的有关规定，会议形成的决 议合法、有效。 二、董事会会议审议情况 （一） 审议通过《关于<2024 年度董事会工作报告>的议案》 表决结果：同意 7 票，反对 0 票，弃权 0 票。 本议案尚需提交公司 2024 年年度股东大会审议。 （二） 审议通过《关于<2024 年度总经理工作报告>的议案》 表决结果：同意 7 票，反对 0 票，弃权 0 ...

证券代码：688075 证券简称：安旭生物 公告编号：2025-004 杭州安旭生物科技股份有限公司 2024 年度利润分配预案的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： ●每股分配比例：每 10 股派发现金红利 8 元（含税），不进行资本公积转 增股本，不送红股。 本次利润分配符合相关法律法规及公司章程的规定，不触及《科创板股票上 市规则》第 12.9.1 条第一款第（八）项规定的可能被实施其他风险警示的情形， 相关数据及指标如下表： ●本次利润分配以实施权益分派股权登记日登记的总股本为基数，具体日期 将在权益分派实施公告中明确。在实施权益分派的股权登记日前公司总股本发生 变动的，拟维持分配总额不变，相应调整每股分配比例，并将另行公告具体调整 情况。 ●公司未触及《上海证券交易所科创板股票上市规则（2024 年 4 月修订）》 （以下简称《科创板股票上市规则》）第 12.9.1 条第一款第（八）项规定的可能 被实施其他风险警示的情形。 一、利润分配预案内容 （一）利润分配预案的具体内容 经中审 ...

证券代码：688075 证券简称：安旭生物 公告编号：2025-010 杭州安旭生物科技股份有限公司 关于作废 2024 年限制性股票激励计划 部分限制性股票的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 杭州安旭生物科技股份有限公司（以下简称"公司"）于 2025 年 4 月 28 日召开的第二届董事会第十七次会议、第二届监事会第十五次会议，审议通过了 《关于作废 2024 年限制性股票激励计划部分限制性股票的议案》。根据《上市 公司股权激励管理办法》（以下简称"《管理办法》"）等法律法规、规范性文 件及《杭州安旭生物科技股份有限公司 2024 年限制性股票激励计划（草案）》 （以下简称"《激励计划（草案）》"）《杭州安旭生物科技股份有限公司 2024 年限制性股票激励计划实施考核管理办法》（以下简称"《考核管理办法》"） 的有关规定及公司 2024 年第二次临时股东大会的授权，公司董事会同意作废公 司 2024 年限制性股票激励计划（以下简称"本次激励计划"）部分限制性股票 合计 47.80 万股。现将有关事项 ...

Financial Performance - The company's operating revenue for Q1 2025 was CNY 115,296,526.87, a decrease of 10.9% compared to CNY 129,406,701.97 in the same period last year[4]. - Net profit attributable to shareholders decreased by 51.52% to CNY 34,029,618.77 from CNY 70,190,798.47 year-on-year[4]. - The net profit after deducting non-recurring gains and losses increased by 15.95% to CNY 22,760,297.27 compared to CNY 19,629,646.53 in the previous year[4]. - Net profit for Q1 2025 was CNY 34,227,418.43, down 51.3% from CNY 70,334,720.12 in Q1 2024[19]. - Earnings per share for Q1 2025 was CNY 0.27, compared to CNY 0.55 in Q1 2024[20]. - The company reported a decrease in comprehensive income to CNY 32,331,616.02 in Q1 2025 from CNY 70,370,450.36 in Q1 2024[20]. Cash Flow - The net cash flow from operating activities was negative at CNY -11,098,782.01, compared to a positive CNY 1,008,618.28 in the same period last year[4]. - Net cash flow from operating activities was -$11.1 million, a decrease from $1.0 million in the previous period[23]. - Cash paid for operating activities totaled $138.6 million, compared to $166.1 million last year[23]. - Cash received from sales in Q1 2025 was CNY 103,961,347.43, a decrease from CNY 110,735,727.41 in Q1 2024[22]. - The company reported a net increase in cash and cash equivalents of -$31.8 million, compared to an increase of $321.7 million last year[24]. Assets and Liabilities - The total assets at the end of the reporting period were CNY 5,844,995,156.61, reflecting a 1.31% increase from CNY 5,769,310,895.27 at the end of the previous year[5]. - Current assets totaled RMB 4,847,904,481.23, compared to RMB 4,769,982,927.28 at the end of 2024, reflecting a growth of approximately 1.6%[13]. - Total liabilities reached RMB 612,876,253.81, compared to RMB 569,523,608.49 at the end of 2024, marking an increase of about 7.6%[14]. - The company's non-current assets totaled RMB 997,090,675.38, slightly down from RMB 999,327,967.99[14]. - The company's total equity attributable to shareholders was CNY 5,235,733,004.95, reflecting a slight increase from CNY 5,203,599,188.59[15]. Research and Development - Research and development expenses totaled CNY 25,058,704.57, representing an increase of 26.3% from CNY 19,840,217.39 year-on-year[4]. - Research and development expenses rose to CNY 25,058,704.57 in Q1 2025, an increase of 26.5% from CNY 19,840,217.39 in Q1 2024[19]. Non-Recurring Items - The company reported non-recurring gains of CNY 11,269,321.50 after tax, primarily due to government subsidies and other non-operating income[7]. - Other income decreased significantly to CNY 1,725,120.33 in Q1 2025 from CNY 13,159,386.79 in Q1 2024[19]. Inventory and Receivables - The company reported a significant increase in inventory, which stood at RMB 143,539,795.97, compared to RMB 147,167,029.08 previously[13]. - Accounts receivable increased to RMB 283,512,930.50, up from RMB 203,690,596.91, representing a significant rise of approximately 39.2%[13]. Other Information - The total number of ordinary shareholders at the end of the reporting period was 5,935[9]. - The company has not disclosed any new product launches or technological advancements during this reporting period[12]. - There are no significant mergers or acquisitions reported in the current financial period[12].

Financial Performance - The company's revenue for 2024 reached RMB 540,698,462.10, representing a 7.42% increase compared to RMB 503,357,076.78 in 2023[20]. - The net profit attributable to shareholders for 2024 was RMB 192,295,303.31, a significant increase of 35.85% from RMB 141,553,680.39 in 2023[20]. - The net cash flow from operating activities improved to RMB 75,093,227.27 in 2024, recovering from a negative cash flow of RMB -623,082,613.12 in 2023[20]. - The total assets as of the end of 2024 were RMB 5,769,310,895.27, a slight decrease of 0.35% from RMB 5,789,539,225.57 in 2023[20]. - The basic earnings per share for 2024 increased to RMB 1.51, up 36.04% from RMB 1.11 in 2023[21]. - The diluted earnings per share also rose to RMB 1.51, reflecting the same growth rate of 36.04% compared to 2023[21]. - The net profit after deducting non-recurring gains and losses decreased to RMB 37,897,947.37 in 2024, down 27.6% from RMB 52,345,318.72 in 2023[20]. - The gross profit margin decreased by 3.15 percentage points to 39.10% due to rising costs[111]. - The company achieved a revenue of 540.70 million RMB, representing a year-on-year growth of 7.42%[108]. - The net profit attributable to the parent company was 192.30 million RMB, an increase of 35.85% compared to the previous year[108]. Dividend Policy - The company plans to distribute a cash dividend of 8 CNY per 10 shares, totaling approximately 101.67 million CNY for the year, which represents 79.30% of the net profit attributable to shareholders[4]. - The total cash dividend for the year, including interim distributions, amounts to 152.50 million CNY[4]. - The company has a cash dividend policy that allows for profit distribution in cash, stock, or a combination of both, ensuring it does not exceed distributable profits[177]. - The company plans to distribute cash dividends amounting to CNY 101,666,244.00, which represents 52.87% of the net profit attributable to ordinary shareholders in the consolidated financial statements[184]. - The cumulative cash dividend amount over the last three accounting years is CNY 657,199,648.00, with an average net profit of CNY 1,126,174,097.84, resulting in a cash dividend ratio of 58.36%[187]. Research and Development - The company invested 18.69% of its operating revenue in R&D, a decrease of 2.22% compared to the previous year[22]. - The cumulative investment in R&D projects reached ¥578,427,519.68, indicating a strong commitment to innovation and development[87]. - The company has developed 10 new POCT platforms, enhancing its product offerings in the clinical testing market[86]. - The R&D investment as a percentage of operating revenue decreased by 2.22% compared to the previous year, indicating a shift in resource allocation[85]. - The company is actively pursuing new technologies and products, with several projects in various stages of development aimed at enhancing diagnostic capabilities[86]. Market Expansion and Strategy - The company is focusing on expanding its market presence and enhancing its product offerings in the medical device sector[12]. - The company aims to become a leader in the POCT industry, emphasizing its commitment to providing excellent products and services for human health[32]. - The company is exploring growth potential in pet health management, family health management, and medical laboratory sectors[32]. - The company is focusing on expanding its market presence internationally, with significant certifications obtained in Canada (115) and Australia (9)[84]. - The company is committed to developing eight major product series, particularly in drug testing, with a focus on product iteration and providing better services to ensure stable business growth[144]. Compliance and Governance - The company has not reported any significant governance issues that would affect the accuracy of the annual report[6]. - The company has implemented measures to enhance compliance with relevant laws and regulations, including the Securities Law and the Shanghai Stock Exchange listing rules[161]. - The internal control audit report issued by Zhonghuan Accounting Firm confirmed that the company maintained effective financial reporting internal controls as of December 31, 2024[200]. - The independent directors supervise the execution of the company's compensation system and provide review opinions on senior management's compensation[198]. - The company aims to enhance its operational compliance and governance standards to promote sustainable development[161]. Innovation and Technology - The company has established nine major technology platforms in the field of precision medical diagnostics, covering eight areas including drug testing, infectious disease testing, and chronic disease testing[34]. - The company is focusing on technology innovation and global ecological chain layout to drive high-quality development[32]. - The company is actively pursuing innovation in core technologies, with platforms for immunochromatography, dry chemistry, and liquid biochips under development[69]. - The company has developed a dry biochemical technology platform that enhances product performance through enzyme catalysis, membrane immobilization, and multi-detection technology, establishing a competitive advantage in chronic disease detection[71]. - The molecular diagnostics segment is the fastest-growing part of the in vitro diagnostics market, focusing on high-throughput and timely technologies[65]. Risks and Challenges - The company has disclosed potential risks that may adversely affect its operations in the management discussion section[3]. - The company faces risks from intensified market competition and potential declines in market share if it fails to maintain its advantages in R&D and product offerings[98]. - The company is at risk of quality control issues due to the complexity of managing multiple stages in the production and supply chain[100]. - The company faced potential risks from stricter regulations under the new EU IVDR, which could impact its manufacturing capabilities[104]. - The company is exposed to risks from currency fluctuations and international market conditions, as over 90% of its main business income comes from overseas sales[101]. Leadership and Management - The company has maintained a stable leadership structure with no changes in shareholdings among key executives during the reporting period[152]. - The overall compensation structure for executives reflects the company's commitment to aligning performance with shareholder interests[153]. - The management team has undergone changes, with new appointments aimed at strengthening operational efficiency[156]. - The company has established a performance evaluation mechanism for senior management, with annual performance bonuses proposed and approved by the board[198]. - The total remuneration for all directors, supervisors, and senior management at the end of the reporting period amounted to 499.94 million[160].

杭州安旭生物科技股份有限公司 募集资金年度存放与实际使用情况 的鉴证报告 众环专字(2025) 0300063号 目 录 起始页码 鉴证报告 募集资金专项报告 关于募集资金年度存放与实际使用情况的专项报告 ] 您可使用手机"扫一扫"或进入"注册会计师行业统一监管平台（http://acc.mof.gov.cn）" 报告编码: 【 2 5 6 6 0 7 . 0 4 4 5 1 3 2 3 2 2 2 2 2 2 2 2 杭州安旭生物科技股份有限公司 度存放与实际使用情况的鉴证报告 众环专字(2025)0300063 号 杭州安旭生物科技股份有限公司全体股东: 我们接受委托,对后附的杭州安旭生物科技股份有限公司(以下简称"安旭生物公司") 截至 2024 年 12 月 31 日止的《董事会关于公司募集资金年度存放与实际使用情况的专项报 告》进行了鉴证工作。 按照中国证监会发布的《上市公司监管指引 公司募集资金管理和使用的 监管要求》和上海证券交易所发布的《 本易所利创板上市公司自律监管指引第 1 号 -- 规范运作》等有关规定,编制《董事会关于公司募集资金年度存放与实际使用情况的 专项报告》,提供真实、合法、完 ...

杭州安旭生物科技股份有限公司 审计报告 众环审字(2025) 0300320号 m 录 审计报告 | 财务报表 | | | --- | --- | | 合并资产负债表 | | | 合并利润表 | 61 | | 合并现金流量表 | ব | | 合并股东权益变动表 | 5 | | 资产负债表 | 7 | | 利润表 | 0 | | 现金流量表 | 10 | | 股东权益变动表 | 11 | | 财务报表附注 | 13 | | 财务报表附注补充资料 | | 您可使用手机"扫一扫"或进入"注册会计师行业统一监管平台（http://acc.mof 起始页码 审计报告 众环审字(2025) 0300320 号 杭州安旭生物科技股份有限公司全体股东: 一、审计意见 我们审计了杭州安旭生物科技股份有限公司(以下简称"安旭生物公司")财务报表, 包括 2024年 12月 31日的合并及公司资产负债表,2024年度的合并及公司利润表、合并及 公司现金流量表、合并及公司股东权益变动表以及相关财务报表附注。 我们认为,后附的财务报表在所有重大方面按照企业会计准则的规定编制,公允反映了 安旭生物公司 2024年12月 31 舟台并函公 ...